Maturity-onset diabetes of the young (MODY) - in search of ideal diagnostic criteria and precise treatment

Prog Cardiovasc Dis. 2024 Jul-Aug:85:14-25. doi: 10.1016/j.pcad.2024.03.004. Epub 2024 Mar 19.

Abstract

Maturity-onset diabetes of the young (MODY) is a spectrum of clinically heterogenous forms of monogenic diabetes mellitus characterized by autosomal dominant inheritance, onset at a young age, and absence of pancreatic islets autoimmunity. This rare form of hyperglycemia, with clinical features overlapping with type 1 and type 2 diabetes mellitus, has 14 subtypes with differences in prevalence and complications occurrence which tailor therapeutic approach. MODY phenotypes differ based on the gene involved, gene penetrance and expressivity. While MODY 2 rarely leads to diabetic complications and is easily managed with lifestyle interventions alone, more severe subtypes, such as MODY 1, 3, and 6, require an individualized treatment approach to maintain a patient's quality of life and prevention of complications. This review summarizes current evidence on the presentation, diagnosis, and management of MODY, an example of a genetic cause of hyperglycemia that calls for a precision medicine approach.

Keywords: Atypical diabetes; Diabetic complications; Maturity-onset diabetes mellitus; Precision medicine; Single-gene mutation disease.

Publication types

  • Review

MeSH terms

  • Age of Onset
  • Biomarkers / blood
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Type 2* / diagnosis
  • Diabetes Mellitus, Type 2* / epidemiology
  • Diabetes Mellitus, Type 2* / genetics
  • Diabetes Mellitus, Type 2* / therapy
  • Genetic Predisposition to Disease
  • Humans
  • Hypoglycemic Agents* / therapeutic use
  • Phenotype*
  • Precision Medicine
  • Predictive Value of Tests
  • Risk Factors
  • Treatment Outcome

Substances

  • Hypoglycemic Agents
  • Blood Glucose
  • Biomarkers

Supplementary concepts

  • Mason-Type Diabetes